Advertisement

Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg)

Published:September 26, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.07.028
      There is limited knowledge regarding the efficacy and safety of fixed-dose oral anticoagulants in overweight patients because of the possible increased risk of embolism and hemorrhage. This study aimed to evaluate embolic, hemorrhagic, and mortality events in anticoagulated patients, administered both antivitamin K and direct oral anticoagulants based on the body weight (<60 kg, 60 to 100 kg and >100 kg). A retrospective registry-based cohort study including all consecutive patients with a diagnosis of atrial fibrillation between January 2014 and January 2018 in the health area of Vigo (Galicia, Spain) was used (CardioCHUVI‐AF registry; ClinicalTrials.gov identifier: NCT04364516). The final cohort comprised 11,821 AF patients. The cohort was classified into 3 categories: low body weight ([LBW], <60 kg, 924 patients); middle body weight (60 to 100 kg, 9,546 patients); and high body weight ([HBW], >100 kg, 958 patients). Outcomes were predicted using the Fine and Gray model and Cox proportional hazards model when appropriate. Middle body weight was the reference group. No association was found between the weight and major bleeding in the univariate analyses: LBW with a sub-distribution hazard ratio (sHR) of 1.13 (95% confidence interval [CI] 0.92 to 1.41), and HBW with an sHR of 1.02 (95% CI 0.83 to 1.26). Stroke/systemic embolism events occurred in 817 patients (6.6%). In the univariate analyses, we found an association between weight and risk of stroke/systemic embolism: LBW sHR 1.37 (95% CI 1.09 to 1.72), and HBW sHR 0.66 (95% CI 0.49 to 0.89) but no association was found in the multivariable model. The same situation was observed with all-cause death: in the univariable model, LBW presented a hazard ratio of 1.48 (95% CI 1.31 to 1.68) and the HBW group presented a hazard ratio of 0.53 (95%CI 0.44 to 0.63) whereas no significant association was found in the multivariable model. We conclude that in our registry, extreme weights were not related to more events during follow-up.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lavie CJ
        • Pandey A
        • Lau DH
        • Alpert MA
        • Sanders P.
        Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise.
        J Am Coll Cardiol. 2017; 70: 2022-2035
        • Zhu W
        • Wan R
        • Liu F
        • Hu J
        • Huang L
        • Li J
        • Hong K.
        Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review.
        J Am Heart Assoc. 2016; 5: e4006
        • Proietti M
        • Guiducci E
        • Cheli P
        • Lip GY.
        Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials.
        Stroke. 2017; 48: 857-866
        • Steffel J
        • Collins R
        • Antz M
        • Cornu P
        • Desteghe L
        • Haeusler KG
        • Oldgren J
        • Reinecke H
        • Roldan-Schilling V
        • Rowell N
        • Sinnaeve P
        • Vanassche T
        • Potpara T
        • Camm AJ
        Heidbüchel H; External reviewers. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Europace. 2021; 23: 1612-1676
        • De Caterina R
        • Lip GYH.
        The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
        Clin Res Cardiol. 2017; 106: 565-572
        • Martin K
        • Beyer-Westendorf J
        • Davidson BL
        • Huisman MV
        • Sandset PM
        • Moll S.
        Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
        J Thromb Haemost. 2016; 14: 1308-1313
        • Steffel J
        • Verhamme P
        • Potpara TS
        • Albaladejo P
        • Antz M
        • Desteghe L
        • Haeusler KG
        • Oldgren J
        • Reinecke H
        • Roldan-Schilling V
        • Rowell N
        • Sinnaeve P
        • Collins R
        • Camm AJ
        • Heidbüchel H
        • ESC Scientific Document Group
        The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393
        • Wallace JL
        • Reaves AB
        • Tolley EA
        • Oliphant CS
        • Hutchison L
        • Alabdan NA
        • Sands CW
        • Self TH.
        Comparison of initial warfarin response in obese patients versus non-obese patients.
        J Thromb Thrombolysis. 2013; 36: 96-101
        • Soyombo BM
        • Taylor A
        • Gillard C
        • Wilson C
        • Bailey Wheeler J.
        Impact of body mass index on 90-day warfarin requirements: a retrospective chart review.
        Ther Adv Cardiovasc Dis. 2021; 1517539447211012803
        • Rocca B
        • Fox KAA
        • Ajjan RA
        • Andreotti F
        • Baigent C
        • Collet JP
        • Grove EL
        • Halvorsen S
        • Huber K
        • Morais J
        • Patrono C
        • Rubboli A
        • Seljeflot I
        • Sibbing D
        • Siegbahn A
        • Ten Berg J
        • Vilahur G
        • Verheugt FWA
        • Wallentin L
        • Weiss TW
        • Wojta J
        • Storey RF
        Antithrombotic therapy and body mass: an expert position paper of the ESC working group on thrombosis.
        Eur Heart J. 2018; 39: 1672-1686f
        • Schulman S
        • Kearon C
        Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Patel MR
        • Mahaffey KW
        • Garg J
        • Pan G
        • Singer DE
        • Hacke W
        • Breithardt G
        • Halperin JL
        • Hankey GJ
        • Piccini JP
        • Becker RC
        • Nessel CC
        • Paolini JF
        • Berkowitz SD
        • Fox KA
        • Califf RM
        • ROCKET AF Investigators
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • Lopes RD
        • Hylek EM
        • Hanna M
        • Al-Khalidi HR
        • Ansell J
        • Atar D
        • Avezum A
        • Bahit MC
        • Diaz R
        • Easton JD
        • Ezekowitz JA
        • Flaker G
        • Garcia D
        • Geraldes M
        • Gersh BJ
        • Golitsyn S
        • Goto S
        • Hermosillo AG
        • Hohnloser SH
        • Horowitz J
        • Mohan P
        • Jansky P
        • Lewis BS
        • Lopez-Sendon JL
        • Pais P
        • Parkhomenko A
        • Verheugt FW
        • Zhu J
        • Wallentin L
        • ARISTOTLE Committees and Investigators
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • Eikelboom J
        • Oldgren J
        • Parekh A
        • Pogue J
        • Reilly PA
        • Themeles E
        • Varrone J
        • Wang S
        • Alings M
        • Xavier D
        • Zhu J
        • Diaz R
        • Lewis BS
        • Darius H
        • Diener HC
        • Joyner CD
        • Wallentin L
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Giugliano RP
        • Ruff CT
        • Braunwald E
        • Murphy SA
        • Wiviott SD
        • Halperin JL
        • Waldo AL
        • Ezekowitz MD
        • Weitz JI
        • Špinar J
        • Ruzyllo W
        • Ruda M
        • Koretsune Y
        • Betcher J
        • Shi M
        • Grip LT
        • Patel SP
        • Patel I
        • Hanyok JJ
        • Mercuri M
        • Antman EM
        • ENGAGE AF-TIMI 48 Investigators
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Wang SY
        • Giugliano RP.
        Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients.
        Am J Cardiol. 2020; 127: 176-183
        • Sandhu RK
        • Ezekowitz J
        • Andersson U
        • Alexander JH
        • Granger CB
        • Halvorsen S
        • Hanna M
        • Hijazi Z
        • Jansky P
        • Lopes RD
        • Wallentin L.
        The ‘obesity paradox’ in atrial fibrillation: observations from the Aristotle (apixaban for Reduction in Stroke and Other thromboembolic Events in atrial fibrillation) trial.
        Eur Heart J. 2016; 37: 2869-2878
        • Zhou Y
        • Ma J
        • Zhu W.
        Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis.
        Am J Cardiovasc Drugs. 2020; 20: 51-60
        • Netley J
        • Howard K
        • Wilson W.
        Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review.
        J Thromb Thrombolysis. 2019; 48: 359-365
        • Overvad TF
        • Rasmussen LH
        • Skjøth F
        • Overvad K
        • Lip GY
        • Larsen TB.
        Body mass index and adverse events in patients with incident atrial fibrillation.
        Am J Med. 2013; 126 (640.e9–640.e17)
        • Lip GYH
        • Merino JL
        • Banach M
        • de Groot JR
        • Maier LS
        • Themistoclakis S
        • Boriani G
        • Jin J
        • Melino M
        • Winters SM
        • Goette A
        Impact of body mass index on outcomes in the edoxaban versus warfarin therapy groups in patients underwent cardioversion of atrial fibrillation (from ENSURE-AF).
        Am J Cardiol. 2019; 123: 592-597
        • Park CS
        • Choi EK
        • Kim HM
        • Lee SR
        • Cha MJ
        • Oh S.
        Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants.
        Heart Rhythm. 2017; 14: 501-507
        • Barba R
        • Marco J
        • Martín-Alvarez H
        • Rondon P
        • Fernández-Capitan C
        • Garcia-Bragado F
        • Monreal M
        • RIETE investigators
        The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE).
        J Thromb Haemost. 2005; 3: 856-862
        • Sebaaly J
        • Kelley D.
        Direct oral anticoagulants in obesity: an updated literature review.
        Ann Pharmacother. 2020; 54: 1144-1158